Showing 1 - 6 of 6 results
The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment. This study will enroll participants with any tumors harboring the NTRK gene fusion including Soft Tissue Sarcomas, Central Nervous System, Melanoma, and Thyroid cancers.
Children's Hospital of Philadelphia and Childrens National Hospital are studying daily living skills like cooking, cleaning, and money management and their impact on quality of life for autistic individuals. This study is funded by the National Institutes of Health (NIH) and is led by Ben Yerys, PhD and Lauren Kenworthy, PhD.
The Synovial Sarcoma Registry and Biospecimen Repository was opened in June of 2023 with the goal of furthering research and improving outcomes for patients with synovial sarcoma. This study is open to anyone treated in the United States. You do NOT have to travel to Philadelphia to participate.
The purpose of this study is to understand how children's brains process sounds and language. Children with Autism Spectrum Disorder (ASD), Intellectual and Developmental Delay (IDD), or Developmental Language Disorder (DLD) often have trouble understanding sounds that are too close together compared to Typically Developing Controls (children without ASD, IDD, or DLD). Fast changes in speech can be hard for children. This may be awkward during conversations and difficult in social situations. This research will see if trouble with processing sounds contributes to language difficulties in children with ASD, IDD, and/or DLD.
This study involves an investigational cellular therapy called Afamitresgene Autoleucel. The overall goal of this study is to find out how safe and effective this cellular therapy is in treating people that have been diagnosed with synovial sarcoma, malignant peripheral nerve sheath tumors (MPNST), neuroblastoma or osteosarcoma that has grown or returned after being treated.
This study enrolls patients with refractory, progressive, or relapsed solid tumors. The purpose of this study is to find out whether a drug called PEEL-224 ("the study drug") is safe and effective when given as monotherapy (a drug given by itself) and as part of a combination therapy together with other chemotherapy drugs.